Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Operating Income of -$5.29 million for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$5.29M | -16.8% |
| 2024 | -$4.53M | -56.2% |
| 2023 | -$2.90M | +15.4% |
| 2022 | -$3.43M | +26.6% |
| 2021 | -$4.67M | +5.9% |
| 2020 | -$4.96M | +21.2% |
| 2019 | -$6.30M | +21.8% |
| 2018 | -$8.05M | +39.5% |
| 2017 | -$13.32M | +45.7% |
| 2016 | -$24.51M | +0.6% |
| 2015 | -$24.65M | -95.2% |
| 2014 | -$12.63M | +3.0% |
| 2013 | -$13.03M | +9.1% |
| 2012 | -$14.34M | +33.1% |
| 2011 | -$21.44M | -3.6% |
| 2010 | -$20.69M | -67.9% |
| 2009 | -$12.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.28M | -33.5% | +29.2% |
| June 30, 2025 | -$1.80M | -126.5% | -64.0% |
| March 31, 2025 | -$1.10M | -145.5% | -14.9% |
| September 30, 2024 | -$955.7K | -33.8% | -20.2% |
| June 30, 2024 | -$794.9K | +0.7% | -77.7% |
| March 31, 2024 | -$447.3K | +42.8% | +37.4% |
| September 30, 2023 | -$714.1K | -7.2% | +10.8% |
| June 30, 2023 | -$800.2K | +25.8% | -2.3% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -16.8% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s operating income has grown by 57.0% (from -$12.33 million to -$5.29 million).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: